CD82 Polypeptide Therapy for Muscular Dystrophy Membrane Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Duchenne Muscular Dystrophy (DMD) are ineffective in providing long-term relief, as they fail to effectively suppress the primary pathology of muscle degeneration caused by dystrophin deficiency, leading to progressive muscle weakness and degeneration.
Innovation Solution
The use of CD82 polypeptides or polynucleotides to increase muscle cell membrane integrity and myofiber structure by enhancing the expression of CD82 in muscle cells or muscle progenitor cells, either through viral vectors like lentiviral or adeno-associated viral vectors, or compounds such as sodium pyruvate, dexamethasone, and oxandrolone, to treat muscular dystrophies and related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for DMD, then muscle function is temporarily maintained, but muscle degeneration progresses and therapy effectiveness is limited
Solution Approach 1:
The patent employs preliminary action by using viral vectors (AAV, lentivirus) to deliver and establish CD82 gene expression before significant muscle degeneration occurs. The transduction of muscle cells with CD82-expressing vectors creates long-term protective effects, addressing the limitation of temporary relief in current therapies. This proactive approach establishes therapeutic effect that persists throughout the disease progression.
Solution Approach 2:
The patent applies parameter changes by modifying the expression level of CD82 protein in muscle cells through viral vector delivery. By increasing CD82 expression beyond physiological levels, the therapy enhances membrane stability and muscle cell protection, thereby improving therapy effectiveness and extending duration of action beyond what current treatments achieve.
2Stability of the object's composition
If dystrophin deficiency is present, then muscle membrane integrity is compromised, but no effective long-term therapy exists to restore it
Solution Approach 1:
The patent uses CD82 as an intermediary molecule to compensate for dystrophin deficiency. CD82 acts as a mediator that interacts with the dystrophin-glycoprotein complex and stabilizes muscle membrane integrity through alternative pathways. This intermediary approach provides therapeutic relief when primary dystrophin function is lost, addressing the unmet need for effective therapy.
Solution Approach 2:
The patent employs composite therapeutic materials by combining viral vectors (AAV or lentivirus) with CD82 polynucleotide sequences. This composite approach delivers sustained CD82 expression to muscle cells, providing long-term restoration of membrane integrity where no effective therapy previously existed.
3Strength
If muscle degeneration is accelerated, then muscle strength decreases, but current therapies cannot suppress the primary pathology
Solution Approach 1:
The patent applies preliminary anti-action by establishing CD82 expression in muscle cells before severe degeneration occurs. The CD82 protein provides protective effects that counteract the primary pathology of muscle degeneration, preventing rather than just treating muscle weakness. This proactive suppression of pathology maintains muscle strength more effectively than current reactive therapies.
Data Source
AI summary
The present invention features compositions and methods featuring CD82 for treating muscular dystrophies and related disorders. In one aspect, the invention provides a method of preserving or increasing muscle function in a dystrophic cell, the method involving contacting the cell with a CD82 polypeptide or a polynucleotide encoding a CD82 polypeptide.